X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5137) 5137
Newsletter (42) 42
Book Chapter (40) 40
Magazine Article (5) 5
Newspaper Article (4) 4
Dissertation (2) 2
Government Document (2) 2
Book Review (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3334) 3334
life sciences & biomedicine (3270) 3270
humans (2924) 2924
male (2747) 2747
midazolam (2633) 2633
midazolam - pharmacology (2026) 2026
female (1852) 1852
pharmacology & pharmacy (1683) 1683
animals (1649) 1649
adult (1417) 1417
midazolam - administration & dosage (1170) 1170
middle aged (1009) 1009
midazolam - pharmacokinetics (825) 825
rats (818) 818
anesthesiology (668) 668
dose-response relationship, drug (662) 662
drug interactions (635) 635
abridged index medicus (588) 588
aged (525) 525
neurosciences & neurology (502) 502
hypnotics and sedatives - pharmacology (495) 495
time factors (443) 443
anesthesia (438) 438
neurosciences (436) 436
adolescent (434) 434
midazolam - blood (418) 418
double-blind method (411) 411
hypnotics and sedatives - administration & dosage (384) 384
pharmacokinetics (383) 383
midazolam - therapeutic use (381) 381
child (352) 352
benzodiazepines (349) 349
midazolam - metabolism (345) 345
benzodiazepines - pharmacology (334) 334
cytochrome p-450 cyp3a - metabolism (332) 332
anti-anxiety agents - pharmacology (322) 322
flumazenil - pharmacology (315) 315
propofol (315) 315
cytochrome p-450 enzyme system - metabolism (310) 310
heart rate - drug effects (303) 303
administration, oral (296) 296
propofol - pharmacology (293) 293
blood pressure - drug effects (292) 292
research (284) 284
analysis (283) 283
child, preschool (282) 282
prospective studies (278) 278
rats, sprague-dawley (274) 274
rats, wistar (273) 273
midazolam - adverse effects (269) 269
pharmacology (269) 269
cytochrome p-450 cyp3a (265) 265
anesthetics, intravenous - pharmacology (259) 259
injections, intravenous (252) 252
area under curve (247) 247
sedation (241) 241
pediatrics (236) 236
ketamine (230) 230
young adult (230) 230
hemodynamics - drug effects (228) 228
cross-over studies (221) 221
cytochrome p-450 (221) 221
veterinary sciences (221) 221
mice (219) 219
gaba modulators - pharmacology (210) 210
infant (202) 202
dosage and administration (197) 197
conscious sedation (196) 196
diazepam - pharmacology (194) 194
pharmacology/toxicology (194) 194
infusions, intravenous (189) 189
midazolam - antagonists & inhibitors (189) 189
ketamine - pharmacology (188) 188
kinetics (182) 182
benzodiazepine (180) 180
fentanyl (180) 180
toxicology (180) 180
medicine & public health (179) 179
psychiatry (179) 179
surgery (179) 179
cytochrome p450 (177) 177
respiration - drug effects (177) 177
conscious sedation - methods (175) 175
drugs (175) 175
in vitro techniques (173) 173
treatment outcome (173) 173
half-life (170) 170
preanesthetic medication (169) 169
anesthesia recovery period (165) 165
general & internal medicine (162) 162
models, biological (159) 159
drug therapy (156) 156
drug therapy, combination (155) 155
fentanyl - pharmacology (154) 154
metabolism (151) 151
hypnotics and sedatives - pharmacokinetics (150) 150
hypnotics and sedatives - therapeutic use (150) 150
cyp3a (149) 149
flumazenil (149) 149
aged, 80 and over (148) 148
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5034) 5034
Japanese (98) 98
French (59) 59
Spanish (50) 50
German (47) 47
Chinese (27) 27
Portuguese (19) 19
Russian (16) 16
Italian (12) 12
Turkish (4) 4
Korean (3) 3
Dutch (2) 2
Bulgarian (1) 1
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Psychopharmacology (Berlin, Germany), ISSN 1432-2072, 03/2013, Volume 228, Issue 2, pp. 321 - 333
Receptor mechanisms underlying the behavioral effects of clinically used nicotinic acetylcholine receptor agonists have not been fully established.Drug... 
Drug discrimination | Neurosciences | Agonist | Varenicline | Cytisine | Efficacy | Mecamylamine | Biomedicine | Mouse | Antagonist | Dihydro-β-erythroidine | Pharmacology/Toxicology | Psychiatry | Nicotine | Pharmacology & Pharmacy | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Nicotine - administration & dosage | Dihydro-beta-Erythroidine - pharmacology | Male | Nicotine - pharmacology | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Discrimination Learning - drug effects | Tobacco Use Cessation Products | Mecamylamine - pharmacology | Nicotinic Agonists - pharmacology | Quinolizines - administration & dosage | Receptors, Nicotinic - drug effects | Receptors, Nicotinic - metabolism | Alkaloids - pharmacology | Morphine - pharmacology | Quinoxalines - administration & dosage | Mice, Inbred C57BL | Quinolizines - pharmacology | Benzazepines - pharmacology | Smoking Cessation - methods | Nicotinic Agonists - administration & dosage | Animals | Alkaloids - administration & dosage | Azocines - pharmacology | Benzazepines - administration & dosage | Mice | Azocines - administration & dosage | Midazolam - pharmacology | Smoking cessation programs | Dosage and administration | Health aspects | Smoking cessation | Pharmacology | Rodents | Index Medicus | dihydro-β-erythroidine | mecamylamine | varenicline | mouse | nicotine | drug discrimination | agonist | antagonist | cytisine | efficacy
Journal Article
Psychopharmacology, ISSN 0033-3158, 1/2014, Volume 231, Issue 1, pp. 181 - 190
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 11/2007, Volume 35, Issue 11, pp. 2119 - 2126
Predicting drug-drug interactions requires an assessment of the drug concentration available to the enzyme active site, both in vivo, and within an in vitro... 
Tolbutamide - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 CYP3A | Microsomes, Liver - metabolism | Cytochrome P-450 Enzyme System - metabolism | Dextromethorphan - metabolism | Male | Fluconazole - metabolism | Quinine - pharmacology | Microsomes, Liver - enzymology | Tolbutamide - metabolism | Fluoxetine - pharmacology | Dextromethorphan - pharmacology | Enzyme Inhibitors - metabolism | Enzyme Inhibitors - pharmacology | Fluvoxamine - pharmacokinetics | Ketoconazole - pharmacokinetics | Rats | Rats, Sprague-Dawley | Catalysis - drug effects | Miconazole - pharmacokinetics | Miconazole - pharmacology | Fluoxetine - metabolism | Cytochrome P-450 CYP2D6 - metabolism | Kinetics | Midazolam - pharmacology | Hepatocytes - enzymology | Cytochrome P-450 CYP2D6 Inhibitors | Quinine - pharmacokinetics | Fluconazole - pharmacology | Tolbutamide - pharmacokinetics | Fluoxetine - pharmacokinetics | Ketoconazole - metabolism | Hepatocytes - metabolism | Ketoconazole - pharmacology | Hepatocytes - cytology | Enzyme Inhibitors - pharmacokinetics | Phenytoin - pharmacology | Dextromethorphan - pharmacokinetics | Phenytoin - metabolism | Quinine - metabolism | Fluvoxamine - metabolism | Cells, Cultured | Midazolam - pharmacokinetics | Fluvoxamine - pharmacology | Miconazole - metabolism | Fluconazole - pharmacokinetics | Animals | Midazolam - metabolism | Phenytoin - pharmacokinetics | Index Medicus
Journal Article